Lundbeck is planning to transition its commercial operations in Israel to be managed by Swixx Group per 1 December, 2025.

For more information, we refer to Lundbeck's press release.

Ruled, but not ruined, by migraine

Audrey Craven knows the isolation migraine can cause. When her migraines were at their worst, Audrey Craven vowed to use her experience to help others navigate their migraine journey and feel less alone.

Read Story

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.